Utilizing nanomaterials for cancer treatment and diagnosis: an overview
- PMID: 39718700
- PMCID: PMC11668726
- DOI: 10.1186/s11671-024-04128-z
Utilizing nanomaterials for cancer treatment and diagnosis: an overview
Abstract
Cancer is a deadly disease with complex pathophysiological nature and is the leading cause of death worldwide. Traditional diagnosis methods often detect cancer at a considerably critical stage and the conventional methods of treatment like chemotherapy, radiation therapy, targeted therapy, and immunotherapy have several limitations, multidrug resistance, cytotoxicity, and lack of specificity are a few examples. These pose substantial challenge for effective and favourable cancer treatment. The advent of nanotechnology has revolutionized the face of cancer diagnosis and treatment. Nanoparticles, which have a size range of 1-100 nm, are biocompatible and have special optical, magnetic, and electrical capabilities, less toxic, more stable, exhibit permeability and retention effect, and are used for precise targeting. There are several classes of nanoparticles each having their own sets of unique properties. NPs have played an important role in the drug delivery system, overcoming the multi-drug resistance, reducing the side-effects as seen in conventional therapeutic methods and hence able to solve the limitations of conventional methods of diagnosis and treatment. This review discusses the four major classes of nanoparticles (Lipid based NPs, Carbon NPs and Metallic NPs and Polymeric NPs): their discovery and introduction in medical field, unique properties and characteristics, advantages and disadvantages, sub-categories and characteristics of these categories, major area of application in Cancer diagnosis and treatment, and latest methodologies where these are used in cancer treatment.
Keywords: Cancer; Cellular targeting; Chemotherapy; Etc; Multidrug resistance; Nanoparticles.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures
















Similar articles
-
Nanoparticles for Cancer Therapy: Current Progress and Challenges.Nanoscale Res Lett. 2021 Dec 5;16(1):173. doi: 10.1186/s11671-021-03628-6. Nanoscale Res Lett. 2021. PMID: 34866166 Free PMC article. Review.
-
Smart Magnetic Drug Delivery Systems for the Treatment of Cancer.Nanomaterials (Basel). 2023 Feb 26;13(5):876. doi: 10.3390/nano13050876. Nanomaterials (Basel). 2023. PMID: 36903753 Free PMC article. Review.
-
The role of nanoparticles and nanomaterials in cancer diagnosis and treatment: a comprehensive review.Am J Cancer Res. 2023 Dec 15;13(12):5751-5784. eCollection 2023. Am J Cancer Res. 2023. PMID: 38187049 Free PMC article. Review.
-
The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.Curr Med Chem. 2018;25(34):4224-4268. doi: 10.2174/0929867324666170830113755. Curr Med Chem. 2018. PMID: 28875844 Review.
-
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.Drug Resist Updat. 2017 Mar;31:15-30. doi: 10.1016/j.drup.2017.05.002. Epub 2017 May 21. Drug Resist Updat. 2017. PMID: 28867241 Review.
Cited by
-
Clinical Applications of Targeted Nanomaterials.Pharmaceutics. 2025 Mar 17;17(3):379. doi: 10.3390/pharmaceutics17030379. Pharmaceutics. 2025. PMID: 40143042 Free PMC article. Review.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
-
- The L. GLOBOCAN 2018: counting the toll of cancer. Lancet. 2018;392(10152):985. - PubMed
-
- Chan H-K, Ismail S. Side effects of chemotherapy among cancer patients in a Malaysian general hospital: experiences, perceptions and informational needs from clinical pharmacists. Asian Pac J Cancer Prev. 2014;15(13):5305–9. 10.7314/apjcp.2014.15.13.5305. - PubMed
-
- Kroemer G, Zitvogel L. The breakthrough of the microbiota. Nat Rev Immunol. 2018;18:87–8. 10.1038/nri.2018.4. - PubMed
Publication types
LinkOut - more resources
Full Text Sources